Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis is attractive because envudeucitinib showed a differentiated safety profile with no MACE or malignancies and lower SAE, TEAE, and discontinuation rates than placebo, while phase III psoriasis data also suggested deepening efficacy over time and broad quality-of-life benefits. Although it missed the overall-population endpoints, the company still appears to have a credible psoriasis asset with comparable efficacy to Takeda’s zasocitinib and a clearer near-term catalyst in the 3Q26 SLE readout. That SLE study in 408 patients could validate the pipeline-in-a-pill thesis and expand the addressable opportunity, supporting the view that envu could drive about $81.3 million in peak 2035E sales under current assumptions.

Alumis is hampered by a weak clinical readout in the ALMS program, where envu missed key endpoints in SLE and the IFNGS-low subgroup showed an unclear inverse dose-response alongside an unusually high 47.5% placebo response in BICLA, raising doubts about the consistency and durability of efficacy. While the IFNGS-high subgroup suggests genuine TYK2 biology, that narrow signal does not fully de-risk a broader regulatory path, especially with management still needing to clarify next steps in the upcoming months and with systemic lupus only assigned a 20% approval probability in the company’s own framework. Financially, the story is also burdened by development and commercialization risk, with estimated end-3Q27 cash of about $109M, 155M shares outstanding, and a likely need for additional capital that could dilute shareholders before profitability.